| PRU |
Report |
Adjusted Operating EPS |
BEAT |
pred ~$3.48 vs. cons $3.42 |
MEDIUM |
| PRU |
Report |
Total Revenue |
IN-LINE |
pred ~$14.25B vs. cons $14.15B |
LOW |
| PRU |
Report |
Group Insurance Benefit Ratio |
BEAT |
pred ~83.5% vs. cons 84.5% |
MEDIUM |
| PRU |
Guide |
FY2026 Effective Tax Rate |
UNCHANGED |
guide ~21-22% vs. cons ~22% (FY2026) |
HIGH |
| PRU |
Guide |
POJ Cumulative 2026 Pretax AOI Drag |
UNCHANGED |
guide ~-$550M vs. cons ~-$550M (FY2026) |
HIGH |
| PRU |
Guide |
Corporate & Other Segment Loss |
LOWER |
guide ~-$720M vs. cons ~-$650M (FY2026, H2-weighted) |
LOW |
| PRU |
Guide |
Long-term Adjusted Operating ROE Target (Strategic Update) |
BETTER |
guide ~16% vs. cons/current 15% (multi-year target) |
LOW |
| PRU |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| PRU |
Return |
5-day cumulative residual |
-2.8% (FADE) |
Stock has already rallied ~25% into the print pricing in Japan-remediation progress and a strong strategic reveal, so even a modest EPS beat and reiterated 2026 guidance offers limited fresh upside; the implicit 2027 POJ earnings drag (~$400-450M) and lingering alt-income/assumption-update noise give analysts room to trim out-period estimates even after an in-line-to-slight-beat quarter, while any lack of concrete new financial targets in the strategic update risks profit-taking after such a large run-up, pulling the stock back over the following days. |
LOW |